Albert WÃ¶lfler

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3886131/publications.pdf

Version: 2024-02-01

64 papers	1,792 citations	257450 24 h-index	289244 40 g-index
66 all docs	66 docs citations	66 times ranked	2982 citing authors

#	Article	IF	Citations
1	Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations. Annals of Hematology, 2022, 101, 837-846.	1.8	5
2	Austrian recommendations for the management of essential thrombocythemia. Wiener Klinische Wochenschrift, 2021, 133, 52-61.	1.9	2
3	Micro-RNA-125a mediates the effects of hypomethylating agents in chronic myelomonocytic leukemia. Clinical Epigenetics, 2021, 13, 1.	4.1	57
4	EZH2 inactivation in RAS-driven myeloid neoplasms hyperactivates RAS-signaling and increases MEK inhibitor sensitivity. Leukemia, 2021, 35, 1521-1526.	7.2	3
5	Advanced isolated light chain amyloid cardiomyopathy with negative immunofixation and normal free light chain ratio. ESC Heart Failure, 2021, 8, 3397-3402.	3.1	3
6	Pulmonary embolism and thrombocytopenia following ChAdOx1 vaccination. Lancet, The, 2021, 397, 1842.	13.7	25
7	SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia treated with immunoglobulin and argatroban. Lancet, The, 2021, 397, e19.	13.7	23
8	miR-23a mediates resistance to hypomethylating agents in myeloid neoplasms. Annals of Hematology, 2021, 100, 2845-2847.	1.8	1
9	Successful management of vaccine-induced immune thrombotic thrombocytopenia-related cerebral sinus venous thrombosis after ChAdOx1 nCov-19 vaccination. Stroke and Vascular Neurology, 2021, , svn-2021-001142.	3.3	20
10	Loss of RAF kinase inhibitor protein is involved in myelomonocytic differentiation and aggravates RAS-driven myeloid leukemogenesis. Haematologica, 2020, 105, 375-386.	3.5	11
11	The role of germline mutation profiling in the selection of related donors for haematopoietic stem cell transplantation. Bone Marrow Transplantation, 2020, 55, 1502-1505.	2.4	3
12	TNFÎ± Rescues Dendritic Cell Development in Hematopoietic Stem and Progenitor Cells Lacking C/EBPÎ±. Cells, 2020, 9, 1223.	4.1	3
13	AÂmulticenter retrospective evaluation of Chronic Myeloid Leukemia (CML) therapy in Austria assessing the impact of early treatment response on patient outcomes in aÂreal-life setting. Wiener Klinische Wochenschrift, 2020, 132, 415-422.	1.9	0
14	Sensitive and broadly applicable residual disease detection in acute myeloid leukemia using flow cytometryâ€based leukemic cell enrichment followed by mutational profiling. American Journal of Hematology, 2020, 95, 1148-1157.	4.1	13
15	Increased Expression of Micro-RNA-23a Mediates Chemoresistance to Cytarabine in Acute Myeloid Leukemia. Cancers, 2020, 12, 496.	3.7	12
16	Feasibility and safety of using an automated decision support system for insulin therapy inÂthe treatment of steroidâ€induced hyperglycemia in patients with acute graftâ€versusâ€host disease: A randomized trial. Journal of Diabetes Investigation, 2019, 10, 339-342.	2.4	8
17	Using Interleukin 6 and 8 in Blood and Bronchoalveolar Lavage Fluid to Predict Survival in Hematological Malignancy Patients With Suspected Pulmonary Mold Infection. Frontiers in Immunology, 2019, 10, 1798.	4.8	19
18	Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection. Nature Communications, 2019, 10, 4666.	12.8	146

#	Article	IF	Citations
19	High GPR56 surface expression correlates with a leukemic stem cell gene signature in CD34â€positive AML. Cancer Medicine, 2019, 8, 1771-1778.	2.8	22
20	Detection of AML-specific TP53 mutations in bone marrowâ€“derived mesenchymal stromal cells cultured under hypoxia conditions. Annals of Hematology, 2019, 98, 2019-2020.	1.8	4
21	Clinical implications of subclonal TP53 mutations in acute myeloid leukemia. Haematologica, 2019, 104, 516-523.	3.5	65
22	Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3KÎ´ in Mature B-cell Malignancies. Clinical Cancer Research, 2018, 24, 1103-1113.	7.0	18
23	Loss of RKIP is a frequent event in myeloid sarcoma and promotes leukemic tissue infiltration. Blood, 2018, 131, 826-830.	1.4	10
24	Antifungal Prophylaxis with Posaconazole Delayed-Release Tablet and Oral Suspension in a Real-Life Setting: Plasma Levels, Efficacy, and Tolerability. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	41
25	Detection of prognostically relevant mutations and translocations in myeloid sarcoma by next generation sequencing. Leukemia and Lymphoma, 2018, 59, 501-504.	1.3	41
26	The frequency of occurrence of fish-shaped red blood cells in different haematologic disorders. Clinical Chemistry and Laboratory Medicine, 2018, 56, 323-326.	2.3	0
27	Residual disease detection using targeted parallel sequencing predicts relapse in cytogenetically normal acute myeloid leukemia. American Journal of Hematology, 2018, 93, 23-30.	4.1	16
28	Realâ€world challenges and unmet needs in the diagnosis and treatment of suspected invasive pulmonary aspergillosis in patients with haematological diseases: An illustrative case study. Mycoses, 2018, 61, 201-205.	4.0	27
29	Diagnosis of invasive aspergillosis in hematological malignancy patients: Performance of cytokines, Asp LFD, and Aspergillus PCR in same day blood and bronchoalveolar lavage samples. Journal of Infection, 2018, 77, 235-241.	3.3	78
30	Ruxolitinib therapy for myelofibrosis in Austria. Wiener Klinische Wochenschrift, 2018, 130, 495-504.	1.9	5
31	Austrian recommendations for the management of polycythemia vera. Wiener Klinische Wochenschrift, 2018, 130, 535-542.	1.9	3
32	Galactomannan testing andAspergillusPCR in same-day bronchoalveolar lavage and blood samples for diagnosis of invasive aspergillosis. Medical Mycology, 2017, 55, myw102.	0.7	65
33	Red blood cell morphology in patients with Î²-thalassemia minor. Laboratoriums Medizin, 2017, 41, 49-52.	0.6	2
34	Somatic TP53 mutations characterize preleukemic stem cells in acute myeloid leukemia. Blood, 2017, 129, 2587-2591.	1.4	44
35	Preâ€fibrotic/early primary myelofibrosis vs. WHOâ€defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease. American Journal of Hematology, 2017, 92, 885-891.	4.1	47
36	Early Hyperglycemia after Initiation of Glucocorticoid Therapy Predicts Adverse Outcome in Patients with Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2017, 23, 1186-1192.	2.0	13

#	Article	IF	Citations
37	Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement. Wiener Klinische Wochenschrift, 2017, 129, 293-302.	1.9	6
38	Essential thrombocythemia vs. pre-fibrotic/early primary myelofibrosis: discrimination by laboratory and clinical data. Blood Cancer Journal, 2017, 7, 643.	6.2	11
39	Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis. Blood, 2017, 130, 946-948.	1.4	52
40	Evidence for a role of decitabine in the treatment of myeloid sarcoma. Annals of Hematology, 2017, 96, 505-506.	1.8	20
41	Therapeutic Resistance in Acute Myeloid Leukemia: The Role of Non-Coding RNAs. International Journal of Molecular Sciences, 2016, 17, 2080.	4.1	58
42	Increased Expression of miR-23a Mediates a Loss of Expression in the RAF Kinase Inhibitor Protein RKIP. Cancer Research, 2016, 76, 3644-3654.	0.9	45
43	Acute myeloid leukemia with TP53 germ line mutations. Blood, 2016, 128, 2270-2272.	1.4	39
44	Infections in patients with acute myeloid leukemia treated with low-intensity therapeutic regimens: Risk factors and efficacy of antibiotic prophylaxis. Leukemia Research, 2016, 42, 47-51.	0.8	17
45	Chemotherapy-Induced Intestinal Mucosal Barrier Damage: a Cause of Falsely Elevated Serum 1,3-Beta-<scp>d</scp> -Glucan Levels?. Journal of Clinical Microbiology, 2016, 54, 798-801.	3.9	17
46	Urine Galactomannan-to-Creatinine Ratio for Detection of Invasive Aspergillosis in Patients with Hematological Malignancies. Journal of Clinical Microbiology, 2016, 54, 771-774.	3.9	20
47	Prognostic potential of 1,3-beta-d-glucan levels in bronchoalveolar lavage fluid samples. Journal of Infection, 2016, 72, 29-35.	3.3	16
48	Diagnostic accuracy of the Aspergillusâ€specific bronchoalveolar lavage lateralâ€flow assay in haematological malignancy patients. Mycoses, 2015, 58, 461-469.	4.0	51
49	Adipose triglyceride lipase acts on neutrophil lipid droplets to regulate substrate availability for lipid mediator synthesis. Journal of Leukocyte Biology, 2015, 98, 837-850.	3.3	64
50	Multicenter evaluation of a lateral-flow device test for diagnosing invasive pulmonary aspergillosis in ICU patients. Critical Care, 2015, 19, 178.	5.8	65
51	Deletion of SPRY4 is a frequent event in secondary acute myeloid leukemia. Annals of Hematology, 2015, 94, 1923-1924.	1.8	5
52	Detection of (1â†'3)â€Î²â€<scp>D</scp>â€glucan in sameâ€day urine and serum samples obtained from patients with haematological malignancies. Mycoses, 2015, 58, 394-398.	4.0	13
53	Germline variants in the SEMA4A gene predispose to familial colorectal cancer type X. Nature Communications, 2014, 5, 5191.	12.8	51
54	Serum and urine galactomannan testing for screening in patients with hematological malignancies. Medical Mycology, 2014, 52, 647-652.	0.7	21

#	Article	IF	Citations
55	Impact of structured personal on-site patient education on low posaconazole plasma concentrations in patients with haematological malignancies. International Journal of Antimicrobial Agents, 2014, 44, 140-144.	2.5	24
56	Myeloid sarcoma in the oral cavity. International Journal of Stomatology & Occlusion Medicine, 2013, 6, 65-69.	0.1	3
57	Frequency, onset and clinical impact of somatic DNMT3A mutations in therapy-related and secondary acute myeloid leukemia. Haematologica, 2012, 97, 246-250.	3.5	46
58	Bronchoalveolar lavage lateral-flow device test for invasive pulmonary aspergillosis diagnosis in haematological malignancy and solid organ transplant patients. Journal of Infection, 2012, 65, 588-591.	3.3	66
59	Germline mutations in the DNA damage response genesBRCA1,BRCA2,BARD1andTP53in patients with therapy related myeloid neoplasms. Journal of Medical Genetics, 2012, 49, 422-428.	3.2	87
60	Lineage-instructive function of C/EBPÎ± in multipotent hematopoietic cells and early thymic progenitors. Blood, 2010, 116, 4116-4125.	1.4	59
61	Siteâ€Specific Ubiquitination Determines Lysosomal Sorting and Signal Attenuation of the Granulocyte Colonyâ€Stimulating Factor Receptor. Traffic, 2009, 10, 1168-1179.	2.7	31
62	Lineage Instructive Function of C/EBPÎ± in Multipotent Hematopoietic Progenitor Cells Revealed in a Novel Cebpa-Cre Knock-in Model. Blood, 2008, 112, 2458-2458.	1.4	0
63	Characterization of a Juxtamembrane Lysine as a Determinant in Lysosomal Routing and Signal Downregulation of the Activated G-CSF Receptor (G-CSFR).. Blood, 2007, 110, 2190-2190.	1.4	2
64	A functional single-nucleotide polymorphism of the G-CSF receptor gene predisposes individuals to high-risk myelodysplastic syndrome. Blood, 2005, 105, 3731-3736.	1.4	47